Metabolic Tumor Volume and Total Lesion Glycolysis in Oropharyngeal Cancer Treated With Definitive Radiotherapy

Which Threshold Is the Best Predictor of Local Control?

Joël Castelli, MD, MSc,†‡ Adrien Depeursinge, PhD,§|| Berardino de Bari, MD,*¶ Anne Devillers, MD,** Renaud de Crevoisier, MD, PhD,†‡†† Jean Bourhis, MD, PhD,* and John O. Prior, MD, PhD‡‡*

Purpose: In the context of oropharyngeal cancer treated with definitive radiotherapy, the aim of this retrospective study was to identify the best threshold value to compute metabolic tumor volume (MTV) and/or total lesion glycolysis to predict local-regional control (LRC) and disease-free survival.

Methods: One hundred twenty patients with a locally advanced oropharyngeal cancer from 2 different institutions treated with definitive radiotherapy underwent FDG PET/CT before treatment. Various MTVs and total lesion glycolysis were defined based on 2 segmentation methods: (i) an absolute threshold of SUV (0–20 g/mL) or (ii) a relative threshold for SUVmax (0%–100%). The parameters' predictive capabilities for disease-free survival and LRC were assessed using the Harrell C-index and Cox regression model.

Results: Relative thresholds between 40% and 68% and absolute threshold between 5.5 and 7 had a similar predictive value for LRC (C-index = 0.65 and 0.64, respectively). Metabolic tumor volume had a higher predictive value than gross tumor volume (C-index = 0.61) and SUVmax (C-index = 0.54). Metabolic tumor volume computed with a relative threshold of 51% of SUVmax was the best predictor of disease-free survival (hazard ratio, 1.23 [per 10 mL], $P = 0.009$) and LRC (hazard ratio: 1.22 [per 10 mL], $P = 0.02$).

Conclusions: The use of different thresholds within a reasonable range (between 5.5 and 7 for an absolute threshold and between 40% and 68% for a relative threshold) seems to have no major impact on the predictive value of MTV. This parameter may be used to identify patient with a high risk of recurrence and who may benefit from treatment intensification.

Key Words: metabolic tumor volume, oropharyngeal cancer, PET, threshold

(*Clin Nucl Med* 2017;42: e281–e285)

^{18}F-FDG PET/CT allows to quantify the metabolic activity of a tumor (glycolysis) and has become a reference tool in oncology for staging, radiotherapy planning, and monitoring tumor response in many cancers.[1,2] Compared with other diagnostic modalities, PET imaging allows a most accurate nodal staging of locally advanced head and neck cancer[3,4] and could result in changing the therapeutic management in nearly 15% of patients.[5]

The SUVmax corresponds to the maximal pixel value in the tumor. Thanks to its ease of use and relative robustness, it is one of the most widely used parameters in clinical practice. However, SUVmax is not representative of nonhomogeneous overall tumor uptake. More recently, volumetric PET parameters—metabolic tumor volume (MTV) and total lesion glycolysis (TLG)—have been correlated with clinical outcome.[6–8] Nonetheless, these parameters require a tumor segmentation that is classically defined by either a percentage of the SUVmax or absolute SUV as the lowest threshold for inclusion. The optimal SUV threshold for clinical outcome prediction in head and neck cancer is not well defined. Few studies have compared different thresholds of MTV and/or TLG,[9–14] and a large majority of studies using the same thresholds of 40% SUVmax[15] or a fixed SUV threshold of greater than 2.5.[16] In the context of oropharyngeal cancer treated with definitive radiotherapy, the aim of this retrospective study was to identify the best threshold value to compute MTV and/or TLG in order to predict clinical outcome.

MATERIALS AND METHODS

All consecutive patients from 1 cancer center and 1 university hospital treated with definitive concurrent chemoradiotherapy or radiotherapy-cetuximab for a locally advanced oropharyngeal carcinoma between January 2010 and December 2015 were retrospectively analyzed. The study enrolled a total of 122 patients. All tumors were locally advanced (stage III or IV, American Joint Committee on Cancer seventh edition).

Treatment and Planning

All patients underwent intensity-modulated radiotherapy using volumetric modulated arc therapy (Rennes) or helical tomotherapy (Lausanne). A total dose of 70 Gy (2 Gy/fraction per day, 35 fractions [Rennes]; or 2.12 Gy/fractions per day, 33 fractions [Lausanne], with a simultaneous integrated boost technique)[17] was delivered combined to concomitant chemotherapy,[18,19] or cetuximab[20] if the patients were not fit for chemotherapy. The modality of planning and treatment were the same as previously described.[21] The study was approved by both institutional ethical committees (NCT02469922).

PET/CT Acquisition

All patients underwent FDG PET/CT for staging before treatment. For (Rennes), the patients lasted at least 4 hours prior to injection of 4 MBq/kg of ^{18}F-FDG (Flucis). Blood glucose levels were checked prior to the injection of ^{18}F-FDG. If not contraindicated, intravenous contrast agents were administered before CT scanning. After a 60-minute uptake period of rest, patients were imaged with

Received for publication October 20, 2016; revision accepted January 15, 2017.
From the *Department of Radiation Oncology, Lausanne University Hospital, Switzerland; †INSERM, U1099, Rennes; ‡Université de Rennes 1, LTSI, Rennes, France; §Ecole Polytechnique Fédérale de Lausanne, Lausanne; and ||University of Applied Sciences Western Switzerland, Sierre, Switzerland; ¶University Hospital Jean Minjoz, INSERM 1098, Besancon; **Nuclear Medicine Department, Centre Eugene Marquis, Rennes; ††Department of Radiation Oncology, Centre Eugene Marquis, Rennes; and ‡‡Nuclear Medicine and Molecular Imaging Department, Lausanne University Hospital, Lausanne, Switzerland.
Conflicts of interest and sources of funding: This work was partly supported by the Swiss National Science Foundation with grant agreement PZ00P2_154891 (to A. Depeursinge). None declared to all other authors.
Correspondence to: Joël Castelli, MD, MSc, Department of Radiation Oncology, Centre Eugene Marquis, avenue de la Bataille Flandre Dunkerque, F-35000 Rennes, France. E-mail: j.castelli@rennes.unicancer.fr.
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
ISSN: 0363-9762/17/4206–e281
DOI: 10.1097/RLU.0000000000001614

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.



FIGURE 1. Illustration of GTV for the primary tumor (GTV T = red line) and for the lymph nodes (GTV N = green line) delineated by the radiation oncologist, for a patient with a T4 N2 oropharyngeal cancer (SUVmax = 9.4 mg/mL). An ROI was computed by adding 3-dimensional margins of 10 mm to GTV-T (ROI-T = purple line) and GTV-N (ROI-N = yellow line). These 2 ROIs were used to compute MTV at different thresholds.

a PET/CT imaging system Discovery ST (General Electric Medical Systems; General Electric Healthcare, Milwaukee, Wis). First, a CT (120 kV, 80 mA, 0.8-second rotation time, slice thickness 3.75 mm) was performed from the base of the skull to the midthigh. PET scanning was performed immediately after acquisition of the CT. Images were acquired from the base of skull to the midthigh (3 min/bed position). PET images were reconstructed by using an ordered-subset expectation maximization iterative reconstruction (2 iterations, 28 subsets) and an iterative fully 3-dimensional image. CT data were used for attenuation calculation. A similar protocol was used in Lausanne, however, on a slightly more recent system, Discovery D690 TOF PET/CT (General Electric Healthcare), which allowed shorter acquisition (2 min/bed position). PET images were reconstructed after time-of-flight and point-spread-function recovery corrections.

PET Analysis

For each patient, tumor gross tumor volume (GTV-T) and nodal GTV (GTV-N) were manually segmented on each PET/CT by the same radiation oncologist, experienced in head and neck cancer treatments. A region of interest (ROI) was computed by adding 3-dimensional margins of 10 mm to GTV-T and GTV-N (Fig. 1).

A set of quantitative parameters based on SUV histograms was extracted from ROI-T and ROI-N in PET images. SUVmax was first computed from ROI-T as the maximum SUV in the delineated volume. Several metabolic volumes were subsequently defined based on 2 segmentation methods: (i) an absolute threshold of SUV (ranging from 0 to 20 g/mL, 0.5-g/mL steps) or (ii) a relative threshold of SUVmax (0%–100%, 1% steps). Metabolic tumor volume was computed as the metabolic volume of the segmented region in milliliters and TLG as SUVmean × MTV of the corresponding thresholded region.

Statistical Analysis

Patients alive at the time of analysis were censored at the date of last follow-up. Disease-free survival (DFS) was calculated from the first day of radiotherapy (chemoradiotherapy) to the date of first event (local or distant recurrence or death). Locoregional control (LRC) was calculated from the first day of radiotherapy to the date of first recurrence in primary tumor and/or lymph node. Follow-up was calculated using a reverse Kaplan-Meier estimation.[22] Disease-free survival and overall survival (OS) estimations were computed using the Kaplan-Meier method, and 2-sided log-rank test was used to compare groups.

The association of the PET pretreatment parameters with DFS and OS was assessed using univariate Cox analyses. Harrell C-index (C-index) was used to compare different models (C-index ≈ 0.5 → not predictive, C-index ≈ 1 → predictive).[23] The C-index was used to determine the optimal SUV threshold giving the most predictive value for each PET parameter. Factors with significance of $P < 0.1$ and with the highest C-index after univariate analysis



FIGURE 2. Volume in milliliters for each relative (**A**) and absolute threshold (**B**). No impact of the ROI was shown as MTV decreases regularly from 0% to 100% and from 0 to 20 mg/mL.

© 2017 Wolters Kluwer Health, Inc. All rights reserved.

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.



FIGURE 3. C-index values for MTV computed with different relative thresholds (from 0% to 100% of SUVmax) (**A**) or with different absolute thresholds (from 0 to 20 mg/mL) (**B**) to predict DFS and LRC. To estimate the predictive capabilities of PET parameters on survival, Harrell C-index values were calculated (C-index) (C-index ≈ 0.5 → not predictive, C-index ≈ 1 → predictive).[23] The C-index was used to identify the threshold that offered the strongest predictive value for MTV.

were assessed for multivariate Cox regression model using backward elimination. Variables were removed from the model if $P > 0.1$.

Two prognostic risk groups were identified based on the estimated optimal cutoff point by the Hothorn and Lausen[24] method. Kaplan-Meier method was used to evaluate this cutoff.

All analyses were performed using R software 3.2.4 (R Development CoreTeam; http://www.r-project.org).

Follow-up

A clinical evaluation was performed after radiotherapy every 3 months the first 2 years then every 6 months. Database was locked on May 30, 2016.

RESULTS

Clinical Outcome

The median follow-up was 38 months (range, 2–80 months). The 2-year DFS was 56.4% (95% confidence interval [CI], 47.3%–67.3%), and the 2-year LRC was 60.7% (95% CI, 51.6%–71.3%). At the analysis, 44 patients had died, and 47 presented a recurrence (20 with locoregional recurrence, 13 with distant recurrence, and 14 with both locoregional and distant recurrence).

Predictive Parameters

Figure 2 shows the correlation between the volume of MTV and the chosen threshold. No limitation in computation of MTV due to the use of an ROI was found.

SUVmax was not correlated with LRC or DFS (C-index = 0.54, $P = 0.63$). No difference was found between MTV and TLG. All thresholds between 40% and 60% of SUVmax or between 4.5 and 6 mg/mL appear to have a similar predictive value (Fig. 3). Relative thresholds lower than 36% or higher than 84% were not significantly correlated with DFS (Fig. 4). The best threshold to predict OS and DFS was 51% of SUVmax, (C-index = 0.68 for OS [hazard ratio, 1.43 per 10 mL; 1.23–1.65; $P < 0.001$]; and C-index = 0.65 for DFS [hazard ratio, 1.43 per 10 mL; 1.23–1.65; $P = 0.03$]). Gross tumor volume was also correlated with DFS (C-index = 0.66, $P = 0.04$) and LRC (C-index = 0.66, $P = 0.03$). In multivariate analysis, MTV 51% was the only significant parameter.

The estimated cutoff point by the Hothorn and Lausen[24] method for the MTV 51% was 22.7 mL. Based on this cutoff, 2 risk groups were identified. The 2-year DFS and LRC were 63.3% (95% CI, 53.2%–75.5%) and 68% (95% CI, 48%–79.7%) for the group with MTV 51% of less than 22.7 mL versus 32.9% (95% CI, 18.7%–58.1%) ($P < 0.001$) and 35.3% (95% CI, 20.4%–61.2%) ($P < 0.001$) for the group with MTV 51% of 22.7 mL or greater ($P = 0.004$) (Fig. 5), respectively.

DISCUSSION

To the best of our knowledge, our study is the first one addressing the issue of the predictive value of a wide range of different thresholds (from 0 to 20 mg/mL and from 0% to 100% of SUVmax) of MTV and TLG in the specific context of oropharyngeal cancers. Considering both primary tumor and lymph node, we found that a relative threshold of 51% was the best predictor for OS and DFS. However, all thresholds between 40% and 62% of SUVmax or between 4.5 and 6 mg/mL appear to have a similar predictive value. The most predictive threshold was 51%, whereas GTV, SUVmax, and parameters computed from absolute SUV threshold appear less predictive. The use of a relative threshold rather than an absolute



FIGURE 4. *P* values for DFS and LRC of MTV computed with different relative thresholds (from 0% to 100% of SUVmax) (**A**) or with different absolute thresholds (from 0 to 20 mg/mL) (**B**).

© 2017 Wolters Kluwer Health, Inc. All rights reserved.

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.



FIGURE 5. Kaplan-Meier curves of DFS (**A**) and LRC (**B**) stratified by MTV computed with a relative threshold of 51% of SUVmax. The population was divided into 2 groups according to the optimal cutoff (Hothorn and Lausen method[24]) of 22.7 mL.

threshold may allow identifying the most metabolic part of the tumor, which may be involved in the recurrence. Relative threshold was also shown to be a better predictor than absolute threshold in a similarly study in cervical cancer.[25] This PET parameter may be used to identify patients with a high risk of recurrence or death, potentially candidates for treatment intensification (eg, dose escalation by dose painting in the MTV).

Several studies also showed a better predictive value of MTV, when compared with GTV and/or American Joint Committee on Cancer staging.[10,26] Noteworthy, the reproducibility of the MTV and/or TLG is limited by the initial definition of these parameters, which is based on a threshold of SUV, absolute (all pixels with SUV value > *x*) or relative (all pixels with SUV value > *xx* % of SUVmax), and most of the studies used only 1 threshold (2.5 or 3 g/mL, or 40%–50%). Six studies compared only 3 or 4 different thresholds of MTV and/or TLG, most often using the same threshold of 40%, 50%, or 2.5 and 3 of absolute SUV.[9–13,27,28] An absolute threshold of 2.5[10,13] and a relative threshold of 40%[9,12] were the best predictors for OS and DFS. However, also, all the other studied thresholds were correlated with OS and DFS but with a lower predictive value. Our study confirms that the use of different relative thresholds within a reasonable range (between 40% and 60%) seems to have no major impact on the predictive value of MTV.

Regarding absolute thresholds, we found a higher value (from 4.5 to 6) than the 2.5 value used routinely.[10,13] However, same result is shown in Abgral et al.[14] This monocentric study compared 14 thresholds (from 2.0 to 7, and 30%, 40%, and 50% of SUVmax) in 80 patients with head and neck cancer treated with surgery and/or radiotherapy. An absolute threshold of 5 was the best one to predict recurrence and death in head and neck cancer. However, the authors computed MTV only for the primary tumor, and not for the lymph nodes.

Another controversial issue is the use of a cutoff value for MTV, which largely varied from 4.9 to 65 mL (median, 13.1 mL).[10,29–32] The use of different thresholds made it difficult to identify the best cutoff to predict clinical outcome. In Abgral et al,[14] a cutoff of 4.9 mL for the MTV 5 was used. However, univariate and multivariate analyses were performed using dichotomized parameters instead of continuous parameters. Dichotomization leads to loss of power, affects the ability to detect relationships, and overestimates the effect size. In our study, in a first step, we used continuous parameters to identify the best threshold (MTV 51%), and in a second step, we used the Hothorn and Lausen[24] method to determine the best cutoff (23 mL).

Our study had some limitations. It was a retrospective analysis, without independent validation. We also calculated MTV with the same threshold for both primary tumor and lymph nodes, instead of using a combination of different thresholds, which may have provided a better predictive value. Despite these limitations, we showed that MTV is an independent prognostic factor, with a higher predictive value than SUVmax and GTV.

CONCLUSIONS

The use of different thresholds within a reasonable range (between 5.5 and 7 for an absolute threshold and between 40% and 68% for a relative threshold) seems to have no major impact on the predictive value of PET parameters. Metabolic tumor volume for both primary tumor and lymph node computed with a relative threshold of 51% of SUV max was the best predictor of OS and DFS. This parameter may be used to identify patients with a high risk of recurrence of death and who may benefit from treatment intensification.

REFERENCES

1. Fletcher JW, Djulbegovic B, Soares HP, et al. Recommendations on the use of ^{18}F-FDG PET in oncology. *J Nucl Med*. 2008;49:480–508.
2. Gambhir SS, Czernin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. *J Nucl Med*. 2001;42:1S–93S.
3. Kyzas PA, Evangelou E, Denaxa-Kyza D, et al. ^{18}F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma+ meta-analysis. *J Natl Cancer Inst*. 2008;100:712–720.
4. Yoo J, Henderson S, Walker-Dilks C. Evidence-based guideline recommendations on the use of positron emission tomography imaging in head and neck cancer. *Clin Oncol (R Coll Radiol)*. 2013;25:e33–e66.
5. Lonneux M, Hamoir M, Reychler H, et al. Positron emission tomography with [^{18}F]fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study. *J Clin Oncol*. 2010;28:1190–1195.
6. Schwartz DL, Harris J, Yao M, et al. Metabolic tumor volume as a prognostic imaging-based biomarker for head-and-neck cancer: pilot results from Radiation Therapy Oncology Group protocol 0522. *Int J Radiat Oncol Biol Phys*. 2015;91:721–729.
7. Moon SH, Choi JY, Lee HJ, et al. Prognostic value of volume-based positron emission tomography/computed tomography in patients with nasopharyngeal carcinoma treated with concurrent chemoradiotherapy. *Clin Exp Otorhinolaryngol*. 2015;8:142–148.
8. Cacicedo J, Navarro A, Del Hoyo O, et al. Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: the point of view of the radiation oncologist. *Br J Radiol*. 2016;89:20160217.
9. Schinagl DA, Span PN, Oyen WJ, et al. Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study. *Eur J Nucl Med Mol Imaging*. 2011;38:1449–1458.
10. Kao CH, Lin SC, Hsieh TC, et al. Use of pretreatment metabolic tumour volumes to predict the outcome of pharyngeal cancer treated by definitive radiotherapy. *Eur J Nucl Med Mol Imaging*. 2012;39:1297–1305.
11. Cheng NM, Fang YH, Lee LY, et al. Zone-size nonuniformity of ^{18}F-FDG PET regional textural features predicts survival in patients with oropharyngeal cancer. *Eur J Nucl Med Mol Imaging*. 2015;42:419–428.

© 2017 Wolters Kluwer Health, Inc. All rights reserved.

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.

12. Lin YC, Chen SW, Hsieh TC, et al. Risk stratification of metastatic neck nodes by CT and PET in patients with head and neck cancer receiving definitive radiotherapy. *J Nucl Med*. 2015;56:183–189.
13. Yabuki K, Shiono O, Komatsu M, et al. Predictive and prognostic value of metabolic tumor volume (MTV) in patients with laryngeal carcinoma treated by radiotherapy (RT)/concurrent chemoradiotherapy (CCRT). *PLoS One*. 2015;10:e0117924.
14. Abgral R, Keromnes N, Robin P, et al. Prognostic value of volumetric parameters measured by ^{18}F-FDG PET/CT in patients with head and neck squamous cell carcinoma. *Eur J Nucl Med Mol Imaging*. 2014;41:659–667.
15. Abgral R, Valette G, Robin P, et al. Prognostic evaluation of percentage variation of metabolic tumor burden calculated by dual-phase FDG PET-CT imaging in patients with head and neck cancer. *Head Neck*. 2016;38(suppl 1):E600–E606.
16. Park GC, Kim JS, Roh JL, et al. Prognostic value of metabolic tumor volume measured by ^{18}F-FDG PET/CT in advanced-stage squamous cell carcinoma of the larynx and hypopharynx. *Ann Oncol*. 2013;24:208–214.
17. Mohan R, Wu Q, Manning M, et al. Radiobiological considerations in the design of fractionation strategies for intensity-modulated radiation therapy of head and neck cancers. *Int J Radiat Oncol Biol Phys*. 2000;46:619–630.
18. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. *N Engl J Med*. 2004;350:1945–1952.
19. Bourhis J, Sire C, Graff P, et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. *Lancet Oncol*. 2012;13:145–153.
20. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. *Lancet Oncol*. 2010;11:21–28.
21. Castelli J, Simon A, Rigaud B, et al. A nomogram to predict parotid gland overdose in head and neck IMRT. *Radiat Oncol*. 2016;11:79.
22. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. *Control Clin Trials*. 1996;17:343–346.
23. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. *Stat Med*. 1996;15:361–387.
24. Hothorn T, Lausen B. On the exact distribution of maximally selected rank statistics. *Comput Stat Data Anal*. 2003;43:121–137.
25. Leseur J, Roman-Jimenez G, Devillers A, et al. Pre- and per-treatment ^{18}F-FDG PET/CT parameters to predict recurrence and survival in cervical cancer. *Radiother Oncol*. 2016;120:512–518.
26. Romesser PB, Lim R, Spratt DE, et al. The relative prognostic utility of standardized uptake value, gross tumor volume, and metabolic tumor volume in oropharyngeal cancer patients treated with platinum based concurrent chemoradiation with a pre-treatment [(18)F] fluorodeoxyglucose positron emission tomography scan. *Oral Oncol*. 2014;50:802–808.
27. Murphy JD, La TH, Chu K, et al. Postradiation metabolic tumor volume predicts outcome in head-and-neck cancer. *Int J Radiat Oncol Biol Phys*. 2011; 80:514–521.
28. Moon SH, Choi JY, Lee HJ, et al. Prognostic value of ^{18}F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: comparisons of volume-based metabolic parameters. *Head Neck*. 2013;35:15–22.
29. Seol YM, Kwon BR, Song MK, et al. Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy. *Acta Oncol*. 2010;49:201–208.
30. Deron P, Mertens K, Goethals I, et al. Metabolic tumour volume. Prognostic value in locally advanced squamous cell carcinoma of the head and neck. *Nuklearmedizin*. 2011;50:141–146.
31. Hentschel M, Appold S, Schreiber A, et al. Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer. *Eur J Nucl Med Mol Imaging*. 2011;38:1203–1211.
32. Kikuchi M, Koyasu S, Shinohara S, et al. Prognostic value of pretreatment ^{18}F-fluorodeoxyglucose positron emission tomography/CT volume-based parameters in patients with oropharyngeal squamous cell carcinoma with known p16 and p53 status. *Head Neck*. 2015;37:1524–1531.

© 2017 Wolters Kluwer Health, Inc. All rights reserved.

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.